Concepedia

Author

Vira Tseluyko

Kharkiv Medical Academy of Postgraduate EducationORCID

Also Known As

Dipen Shah, Ihor Kovalskyi, Kostiantyn Yushko, Mykola Kushnir, Oleg Sychov, Reinhold Kreutz, V J Tseluyko, V Tseluyko, V. I. Tseluyko, V. Tseluyko

118

Publications

4.9K

Citations

21

H-Index

34

Concepts

All Affiliations

Kharkiv Medical Academy of Postgraduate EducationHarvard UniversityUniversity College LondonStanford UniversityBrigham and Women's Hospital
VT

About

Vira Tseluyko is an author at Kharkiv Medical Academy of Postgraduate Education specializing in medicine, cardiovascular disease, and atherosclerosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

2.8K

2

Emergency Medicine

2

2

769

3

Clinical Nutrition

1

1

723

4

Nephrology

1

1

25

5

Neurology

1

1

855

Vira Tseluyko

×

19

Publications

3.9K

Citations

18

H-Index

YearCitations

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom,

The Lancet

2017

855

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch,

The Lancet

2017

749

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker,

The Lancet

2020

723

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler,

The Lancet

2018

251

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Paul Emery, Jiří Vencovský, Anna Sylwestrzak,

Annals of the Rheumatic Diseases

2015

226

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber,

The Lancet

2022

206

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens,

Journal of the American Heart Association

2016

196

A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Michael Yellin, I.A. Paliienko, Andra Bălănescu,

Arthritis & Rheumatism

2011

192

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek,

Circulation

2022

112

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Zien Zhou, Meg Jardine, Qiang Li,

Stroke

2021

111

Page 1